| Literature DB >> 30061674 |
Sang-Hoon Song1, Won-Jun Jang1, Jihye Hwang1, Byoungduck Park1, Jung-Hee Jang2, Young-Ho Seo1, Chae Ha Yang3, Sooyeun Lee4, Chul-Ho Jeong5.
Abstract
Methamphetamine (MA) is a highly addictive psychostimulant that disturbs the central nervous system; therefore, diagnosis of MA addiction is important in clinical and forensic toxicology. In this study, a MA self-administration rat model was used to illustrate the gene expression profiling of the rewarding effect caused by MA. RNA-sequencing was performed to examine changes in gene expression in rat whisker follicles collected before self-administration, after MA self-administration, and after withdrawal sessions. We identified six distinct groups of genes, with statistically significant expression patterns. By constructing the functional association network of these genes and performing the subsequent topological analysis, we identified 43 genes, which have the potential to regulate MA reward and addiction. The gene pathways were then analysed using the Reactome and Knowledgebase for Addiction-Related Gene database, and it was found that genes and pathways associated with Alzheimer's disease and the heparan sulfate biosynthesis were enriched in MA self-administration rats. The findings suggest that changes of the genes identified in rat whisker follicles may be useful indicators of the rewarding effect of MA. Further studies are needed to provide a comprehensive understanding of MA addiction.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30061674 PMCID: PMC6065325 DOI: 10.1038/s41598-018-29772-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Methamphetamine self-administration (MASA). (A) The experimental timeline of saline or methamphetamine self-administration and the sampling time-points of MASA. (B) The number of infusions in saline or methamphetamine self-administration rats. MA self-administered rats (n = 6) had a significantly greater infusion number than did saline self-administration rats (n = 6). Statistical analysis was performed using the two-way analysis of variance (ANOVA) and the student Newman-Keuls test. Error bars represent the mean ± SEM (n = 6). *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 2Quality assessment of RNA-sequencing (RNA-seq) data. (A) Grouping of samples via principal component analysis based on gene expression abundance. (B) Hierarchical clustering of genes. (C) A heat-map of the 8,680 expressed genes. Gene expression abundance decreases from red to green.
Figure 3Gene expression pattern analysis of RNA-seq data. (A) Flow chart of RNA-seq data processing. Transcriptome profiling in whisker follicle samples collected at the three time-points (control [CON], MASA, and withdrawal [WD]). Differentially expressed transcripts among the three time-points were identified through a one-way ANOVA. (B) Gene expression pattern analysis. The expression patterns of genes were classified into six groups. All graphs are expressed as the normalised value of gene expression. (C) The number of genes in each group.
Figure 4Functional association network analysis of differentially expressed genes. (A) Functional association network in MASA and WD rat whisker follicles. Nodes in the same group are coded with the same colour. Orange and red nodes represent up-regulation in MASA and up-down-regulation in WD, respectively. Yellow and green nodes show constant expression in MASA and up-down-regulation in WD, respectively. Cyan and blue nodes show downregulation in MASA and up-down-regulation in WD, respectively. The links between the same colour nodes are displayed using identical colours. (B) A comparison of link numbers “within” and “between” groups. The number of links according to link type. “Within” is a link to the identical group. “Between” is a link to the different groups. (C) Likelihood scores of “within” groups. Statistical analysis was performed using the Mann-Whitney U test. ***P < 0.001. (D) Distribution of addiction-related genes in the network. Links between the same colour nodes are displayed with identical colours. (E) Mean betweenness centrality (BC) scores of the six groups and addiction-related gene group (addiction). Statistical analysis was performed using the Mann-Whitney U test. **p < 0.01. (F) Relative fold-enrichment BC scores of the six groups and addiction-related gene group. Statistical analysis was performed using the hypergeometric test. ***p < 0.001.
List of genes with top 10% betweenness centrality (BC) scores in the network.
| Rank | Genes | Genbank | BC | Addic Re. | Group | Description | Normalised | |
|---|---|---|---|---|---|---|---|---|
| MASA | WD | |||||||
| 1 | Hsp90ab1 | NM_001004082 | 0.2127 | O | G4 | Heat shock protein 90 alpha (cytosolic), class B member 1 (Hsp90ab1) | 0.94 | 0.51 |
| 2 | Akt1 | NM_033230 | 0.1694 | O | G2 | V-akt murine thymoma viral oncogene homolog 1 (Akt1) | 1.58 | 0.80 |
| 3 | Src | NM_031977 | 0.1171 | O | G2 | SRC proto-oncogene, non-receptor tyrosine kinase (Src) | 1.31 | 0.66 |
| 4 | Ranbp2 | NM_001191604 | 0.0671 | G5 | RAN binding protein 2 (Ranbp2) | 0.77 | 1.39 | |
| 5 | Mapk14 | NM_031020 | 0.0586 | G4 | Mitogen activated protein kinase 14 (Mapk14) | 0.96 | 0.58 | |
| 6 | Egfr | NM_031507 | 0.0568 | G2 | Epidermal growth factor receptor (Egfr) | 1.30 | 0.67 | |
| 7 | Prkacb | XM_006233452 | 0.0447 | O | G2 | Protein kinase, cAMP dependent, catalytic, beta (Prkacb), transcript variant X2 | 1.23 | 0.65 |
| 8 | Gnb2l1 | NM_130734 | 0.0436 | G6 | Guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 (Gnb2l1) | 0.78 | 0.45 | |
| 9 | Cav1 | NM_031556 | 0.0419 | G2 | Caveolin 1, caveolae protein (Cav1), transcript variant 1 | 3.53 | 0.52 | |
| 10 | Cdh1 | NM_031334 | 0.0385 | O | G4 | Cadherin 1 (Cdh1) | 1.04 | 0.50 |
| 11 | Cct7 | NM_001106603 | 0.0363 | G6 | Chaperonin containing Tcp1, subunit 7 (eta) (Cct7) | 0.85 | 0.54 | |
| 12 | Itgb1 | NM_017022 | 0.0322 | G2 | Integrin, beta 1 (Itgb1) | 2.02 | 1.16 | |
| 13 | Ppp1ca | NM_031527 | 0.0319 | O | G6 | Protein phosphatase 1, catalytic subunit, alpha isozyme (Ppp1ca) | 0.81 | 0.50 |
| 14 | Actr1a | NM_001106364 | 0.0313 | G4 | ARP1 actin-related protein 1 homolog A, centractin alpha (yeast) (Actr1a) | 0.99 | 0.51 | |
| 15 | Tgfb1 | NM_021578 | 0.0313 | O | G2 | Transforming growth factor, beta 1 (Tgfb1) | 1.75 | 0.34 |
| 16 | Sec61a1 | NM_199256 | 0.0290 | O | G6 | Sec61 alpha 1 subunit (S. cerevisiae) (Sec61a1) | 0.73 | 0.31 |
| 17 | Cdk16 | NM_031077 | 0.0274 | G6 | Cyclin-dependent kinase 16 (Cdk16), transcript variant 2 | 0.85 | 0.51 | |
| 18 | Ywhab | NM_019377 | 0.0262 | O | G6 | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta (Ywhab) | 0.76 | 0.52 |
| 19 | Sdc2 | NM_013082 | 0.0250 | G2 | Syndecan 2 (Sdc2) | 1.77 | 0.67 | |
| 20 | Psmd2 | NM_001031639 | 0.0236 | G6 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 (Psmd2) | 0.77 | 0.45 | |
| 21 | Jak1 | NM_053466 | 0.0232 | G2 | Janus kinase 1 (Jak1) | 1.83 | 1.05 | |
| 22 | Rela | NM_199267 | 0.0232 | G4 | V-rel avian reticuloendotheliosis viral oncogene homolog A (Rela) | 1.04 | 0.56 | |
| 23 | Vcp | NM_053864 | 0.0218 | O | G6 | Valosin-containing protein (Vcp) | 0.78 | 0.51 |
| 24 | Srebf2 | NM_001033694 | 0.0211 | G4 | Sterol regulatory element binding transcription factor 2 (Srebf2) | 0.94 | 0.55 | |
| 25 | Atp5a1 | NM_023093 | 0.0206 | G6 | ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (Atp5a1) | 0.79 | 0.44 | |
| 26 | Nrp1 | NM_145098 | 0.0201 | O | G2 | Neuropilin 1 (Nrp1) | 1.87 | 0.63 |
| 27 | App | NM_019288 | 0.0197 | O | G2 | Amyloid beta (Aβ) precursor protein (App) | 2.71 | 0.83 |
| 28 | Eef1g | NM_001004223 | 0.0197 | O | G6 | Eukaryotic translation elongation factor 1 gamma (Eef1g) | 0.77 | 0.33 |
| 29 | Stat5a | NM_017064 | 0.0191 | G2 | Signal transducer and activator of Transcription 5A (Stat5a) | 2.18 | 0.64 | |
| 30 | Itch | NM_001005887 | 0.0187 | G2 | Itchy E3 ubiquitin protein ligase (Itch) | 1.22 | 0.87 | |
| 31 | Atp1a1 | NM_012504 | 0.0183 | G2 | ATPase, Na+/K+ transporting, alpha 1 polypeptide (Atp1a1) | 1.80 | 0.63 | |
| 32 | Zmiz1 | NM_001108393 | 0.0176 | G2 | Zinc finger, MIZ-type containing 1 (Zmiz1) | 1.72 | 0.68 | |
| 33 | Gli1 | NM_001191910 | 0.0161 | G2 | GLI family zinc finger 1 (Gli1) | 3.78 | 1.42 | |
| 34 | Prkg2 | NM_013012 | 0.0158 | O | G6 | Protein kinase, cGMP-dependent, type II (Prkg2) | 0.51 | 0.09 |
| 35 | Ctbp2 | NM_053335 | 0.0153 | G2 | C-terminal binding protein 2 (Ctbp2) | 1.24 | 0.92 | |
| 36 | Hadhb | NM_133618 | 0.0147 | O | G6 | Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit (Hadhb) | 0.69 | 0.48 |
| 37 | Nfkb2 | NM_001008349 | 0.0144 | G2 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 (Nfkb2) | 1.57 | 0.85 | |
| 38 | Stk11 | NM_001108069 | 0.0143 | G6 | Serine/threonine kinase 11 (Stk11) | 0.82 | 0.43 | |
| 39 | Vcl | NM_001107248 | 0.0141 | G2 | Vinculin (Vcl) | 1.73 | 0.73 | |
| 40 | Pip4k2b | NM_053550 | 0.0136 | O | G2 | Phosphatidylinositol-5-phosphate 4-kinase, type II, beta (Pip4k2b) | 1.46 | 0.74 |
| 41 | Tle3 | NM_053400 | 0.0134 | O | G6 | Transducin-like enhancer of split 3 (Tle3) | 0.70 | 0.35 |
| 42 | Map3k3 | NM_001107058 | 0.0133 | G2 | Mitogen activated protein kinase (Map3k3) | 1.41 | 0.72 | |
| 43 | Fbxw11 | NM_001106993 | 0.0129 | G2 | F-box and WD repeat domain containing 11 (Fbxw11) | 1.16 | 0.68 | |
Biological pathways and genes regulated by MA self-administration.
| Pathways |
|
|
|---|---|---|
|
| ||
| Cell junction organization | Vcl | 0.02 |
| Cell-cell junction organization | ||
| Adherens junctions interactions | Vcl | 0.01 |
|
| ||
| Axon guidance | ||
| L1CAM interactions | ||
| CHL1 interactions | Nrp1, Itgb1 | 0.01 |
|
| ||
| Diseases of signalling transduction | ||
| Signalling by TGF-beta Receptor Complex in Cancer | ||
| Loss of function of TGRBR1 in Cancer | ||
| TGFBR1 LBD Mutants in Cancer | Tgfb1 | 0.05 |
| Loss of function of TGRBR2 in Cancer | ||
| TGFBR2 MSI Frameshift Mutants in Cancer | Tgfb1 | 0.03 |
| Signalling by WNT in cancer | ||
| TCF7L2 mutants-unbinded CTBP | Ctbp2 | 0.04 |
| Oncogenic MAPK signalling | ||
| Signalling by high-kinase activity BRAF mutants | Src, Ywhab, and Vcl | 0.03 |
| Signalling by moderate kinase activity BRAF mutants | Src, Ywhab, and Vcl | 0.05 |
| Paradoxical activation of RAF signalling by kinase inactive BRAF | Src, Ywhab, and Vcl | 0.05 |
| Diseases of Immune System | ||
| Diseases associated with the TLR signalling cascade | ||
| IKBKG deficiency-caused anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | Nfkb2, Rela | 0.01 |
| IkBA variant leads to EDA-ID | Nfkb2, Rela | 0.01 |
|
| ||
| Non-integrin membrane-ECM interactions | ||
| Syndecan interactions | Itgb1, Sdc2 | 0.04 |
|
| ||
| Cell surface interactions at the vasculat wall | ||
| Basigin interactions | Itgb1, cav1 | 0.01 |
|
| ||
| Adaptive immune system | ||
| Costimulation by the CD28 family | ||
| CTLA4 inhibitory signalling | Src and Akt1 | 0.05 |
| Innate Immune System | ||
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | ||
| TRAF6 mediated NF-kB activation | App, Nfkb2, and Rela | 0.02 |
| Cytosolic sensors of pathogen-associated DNA | ||
| ZBP1(DAI) mediated induction of type1 IFNs | ||
| RIP-mediated NFkB activation via ZBP1 | App, Nfkb2, and Rela | 0.03 |
| DEx/H-box helicases-activated type I IFN and inflammatory cytokines production | App, Nfkb2, and Rela | 0.03 |
| C-type lectin receptors (CLRs) | ||
| CLEC7A(Dectin-1) signalling | ||
| Dectin-1 mediated noncanonical NF-kB signalling | Psmd2, Nfkb2, Fbxw11, and Rela | 0.03 |
| Cytokine Signalling in Immune system | ||
| Signalling by Interleukins | ||
| Interleukin-1 family signalling | ||
| Interleukin-1 processing | Nfkb2 and Rela | 0.02 |
|
| ||
| Metabolism of lipids | ||
| Triglyceride metabolism | ||
| Triglyceride catabolism | Cav1, Prkacb, and Ppp1ca | 0.04 |
| Phospholipid metabolism | ||
| PI Metabolism | ||
| Synthesis of PIPs in the nucleus | Pip4k2b | 0.02 |
|
| ||
| Signalling by receptor tyrosine kinases | ||
| Signalling by NGF | ||
| NGF signalling via TRKA from the plasma membrane | ||
| Signalling to ERKs | ||
| Signalling to RAS | ||
| p38MAPK events | Mapk14 and Src | 0.03 |
| Signalling by hedgehog | ||
| Hedgehog ‘on’ state | ||
| GLI proteins bind promoters of Hh responsive genes to promote transcription | Gli1 | 0.04 |
| MAPK family signalling cascades | ||
| RAF/MAP kinase cascade | ||
| MAP2K and MAPK activation | Src, Ywhab, and Vcl | 0.03 |
| Intracellular signalling by second messengers | ||
| PIP3-activated AKT signalling | ||
| Negative regulation of the PI3K/AKT network | Src, Akt1, Pip4k2b, and Egfr | 0.05 |
Figure 5Schematic of the signalling pathways altered in MA self-administration. An increased expression of genes related to Alzheimer’s disease (AD) and heparan sulfate biosynthesis is observed in MASA. Activation of nuclear factor-κB leads to up-regulation of amyloid-β precursor protein, which is associated with AD.